These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. Frew JW; Navrazhina K; Marohn M; Lu PC; Krueger JG Exp Dermatol; 2019 Aug; 28(8):886-891. PubMed ID: 31140657 [TBL] [Abstract][Full Text] [Related]
24. What is hidradenitis suppurativa? Lee EY; Alhusayen R; Lansang P; Shear N; Yeung J Can Fam Physician; 2017 Feb; 63(2):114-120. PubMed ID: 28209676 [TBL] [Abstract][Full Text] [Related]
25. Hidradenitis suppurativa: the role of immune dysregulation. Kelly G; Sweeney CM; Tobin AM; Kirby B Int J Dermatol; 2014 Oct; 53(10):1186-96. PubMed ID: 24961484 [TBL] [Abstract][Full Text] [Related]
26. Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model. Quartey QQ; Miller RJ; Pinsker BL; Okoh UJ; Shipman WD; George BA; Nwizu CC; Barnes LA; Kerns ML; Caffrey JA; Aliu O; Brown ID; Succaria F; Maynard JP; Herbert AS; Kang S; Miller LS; Okoye GA; Byrd AS Clin Exp Dermatol; 2020 Mar; 45(2):202-206. PubMed ID: 31322280 [TBL] [Abstract][Full Text] [Related]
27. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Micheletti RG Semin Cutan Med Surg; 2014 Jun; 33(3 Suppl):S48-50. PubMed ID: 25188457 [TBL] [Abstract][Full Text] [Related]
28. Hidradenitis Suppurativa and Thyroid Disease: Systematic Review and Meta-Analysis. Phan K; Huo YR; Charlton O; Smith SD J Cutan Med Surg; 2020; 24(1):23-27. PubMed ID: 31994934 [TBL] [Abstract][Full Text] [Related]
29. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Campione E; Lanna C; Diluvio L; Cannizzaro MV; Grelli S; Galluzzo M; Talamonti M; Annicchiarico-Petruzzelli M; Mancini M; Melino G; Candi E; Schiavone G; Wang Y; Shi Y; Bianchi L Cell Cycle; 2020 Feb; 19(3):257-267. PubMed ID: 31905036 [TBL] [Abstract][Full Text] [Related]
30. Hidradenitis suppurativa in the pediatric population. Liy-Wong C; Pope E; Lara-Corrales I J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613 [TBL] [Abstract][Full Text] [Related]
32. Hidradenitis Suppurativa: Causes, Features, and Current Treatments. Vinkel C; Thomsen SF J Clin Aesthet Dermatol; 2018 Oct; 11(10):17-23. PubMed ID: 30519375 [TBL] [Abstract][Full Text] [Related]
33. An update on the pathogenesis of hidradenitis suppurativa: implications for therapy. Negus D; Ahn C; Huang W Expert Rev Clin Immunol; 2018 Apr; 14(4):275-283. PubMed ID: 29509041 [TBL] [Abstract][Full Text] [Related]
34. Epidemiologic and clinical features of hidradenitis suppurativa. Parulkar I; Haleem H; Paek SY Semin Cutan Med Surg; 2017 Jun; 36(2):42-46. PubMed ID: 28538742 [TBL] [Abstract][Full Text] [Related]
35. Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019. Narla S; Price KN; Sachdeva M; Shah M; Shi V; Hamzavi I; Alavi A; Lowes MA J Am Acad Dermatol; 2021 Jan; 84(1):120-129. PubMed ID: 32497690 [TBL] [Abstract][Full Text] [Related]
37. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases. Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416 [TBL] [Abstract][Full Text] [Related]